Binds to and depresses opiate receptors in spinal cord and CNS, altering perception of and response to pain
Route Onset Peak Duration
IM, SC 10–15 min 30–60 min 2–4 hr
IV Immediate 5–7 min 2–4 hr
Metabolism: Hepatic; T1/2: 3–8 hr
Distribution: Crosses placenta; enters breast milk
Excretion: Urine
• Moderate to severe pain
• Preoperative sedation
• Analgesia during labor
• Hypersensitivity to drug or bisulfites (with some injectable products)
• MAO inhibitor use within past 14 days
Use cautiously in:
• head trauma; increased intracranial pressure (ICP); severe renal, hepatic, or pulmonary disease; hypothyroidism; adrenal insufficiency; extensive burns; alcoholism
• undiagnosed abdominal pain or prostatic hyperplasia
• elderly or debilitated patients
• pregnant patients (not recommended before labor)
• labor (drug may cause respiratory depression in neonate)
• breastfeeding patients
• children.
Antihistamines, sedative-hypnotics: additive CNS depression
Barbiturates, cimetidine, protease inhibitor antiretrovirals: increased respiratory and CNS depression
Chlorpromazine, thioridazine: increased risk of pethedine toxicity
MAO inhibitors, procarbazine: potentially fatal reaction
Opioid agonist-antagonists: precipitation of opioid withdrawal in physically dependent patients
Phenytoin: increased meperidine metabolism and decreased effects
CNS: confusion, sedation, dysphoria, euphoria, floating feeling, hallucinations, headache, unusual dreams, seizures
CV: hypotension, bradycardia, cardiac arrest, shock
EENT: blurred vision, diplopia, miosis
GI: nausea, vomiting, constipation, ileus, biliary tract spasms
GU: urinary retention
Respiratory: respiratory depression, respiratory arrest
Skin: flushing, sweating, induration
Other: pain at injection site, local irritation, physical or psychological drug dependence, drug tolerance
• Store below 30 C°
• Protect from light and freezing
• Pethidine Injection 50mg / 1ml : 10 ampoules/box
• Pethidine Injection 100mg / 2ml : 10 ampoules/box
-
Injection 100mg/2ml - Injection 50mg/1m
Analgesic, adjunct to anesthesia
Analgesic
category B
Binds to and depresses opiate receptors in spinal cord and CNS, altering perception of and response to pain
Route Onset Peak Duration
IM, SC 10–15 min 30–60 min 2–4 hr
IV Immediate 5–7 min 2–4 hr
Metabolism: Hepatic; T1/2: 3–8 hr
Distribution: Crosses placenta; enters breast milk
Excretion: Urine
• Moderate to severe pain
• Preoperative sedation
• Analgesia during labor
• Hypersensitivity to drug or bisulfites (with some injectable products)
• MAO inhibitor use within past 14 days
Use cautiously in:
• head trauma; increased intracranial pressure (ICP); severe renal, hepatic, or pulmonary disease; hypothyroidism; adrenal insufficiency; extensive burns; alcoholism
• undiagnosed abdominal pain or prostatic hyperplasia
• elderly or debilitated patients
• pregnant patients (not recommended before labor)
• labor (drug may cause respiratory depression in neonate)
• breastfeeding patients
• children.
Antihistamines, sedative-hypnotics: additive CNS depression
Barbiturates, cimetidine, protease inhibitor antiretrovirals: increased respiratory and CNS depression
Chlorpromazine, thioridazine: increased risk of pethedine toxicity
MAO inhibitors, procarbazine: potentially fatal reaction
Opioid agonist-antagonists: precipitation of opioid withdrawal in physically dependent patients
Phenytoin: increased meperidine metabolism and decreased effects
CNS: confusion, sedation, dysphoria, euphoria, floating feeling, hallucinations, headache, unusual dreams, seizures
CV: hypotension, bradycardia, cardiac arrest, shock
EENT: blurred vision, diplopia, miosis
GI: nausea, vomiting, constipation, ileus, biliary tract spasms
GU: urinary retention
Respiratory: respiratory depression, respiratory arrest
Skin: flushing, sweating, induration
Other: pain at injection site, local irritation, physical or psychological drug dependence, drug tolerance
• Store below 30 C°
• Protect from light and freezing
• Pethidine Injection 50mg / 1ml : 10 ampoules/box
• Pethidine Injection 100mg / 2ml : 10 ampoules/box
-
[view] =>-
) ) [field_contraindications] => Array ( [0] => Array ( [value] => • Hypersensitivity to drug or bisulfites (with some injectable products) • MAO inhibitor use within past 14 days [format] => 1 [safe] =>• Hypersensitivity to drug or bisulfites (with some injectable products)
• MAO inhibitor use within past 14 days
• Hypersensitivity to drug or bisulfites (with some injectable products)
• MAO inhibitor use within past 14 days
Injection 100mg/2ml - Injection 50mg/1m
[view] =>Injection 100mg/2ml - Injection 50mg/1m
) ) [field_drug_interactions] => Array ( [0] => Array ( [value] => Antihistamines, sedative-hypnotics: additive CNS depression Barbiturates, cimetidine, protease inhibitor antiretrovirals: increased respiratory and CNS depression Chlorpromazine, thioridazine: increased risk of pethedine toxicity MAO inhibitors, procarbazine: potentially fatal reaction Opioid agonist-antagonists: precipitation of opioid withdrawal in physically dependent patients Phenytoin: increased meperidine metabolism and decreased effects [format] => 1 [safe] =>Antihistamines, sedative-hypnotics: additive CNS depression
Barbiturates, cimetidine, protease inhibitor antiretrovirals: increased respiratory and CNS depression
Chlorpromazine, thioridazine: increased risk of pethedine toxicity
MAO inhibitors, procarbazine: potentially fatal reaction
Opioid agonist-antagonists: precipitation of opioid withdrawal in physically dependent patients
Phenytoin: increased meperidine metabolism and decreased effects
Antihistamines, sedative-hypnotics: additive CNS depression
Barbiturates, cimetidine, protease inhibitor antiretrovirals: increased respiratory and CNS depression
Chlorpromazine, thioridazine: increased risk of pethedine toxicity
MAO inhibitors, procarbazine: potentially fatal reaction
Opioid agonist-antagonists: precipitation of opioid withdrawal in physically dependent patients
Phenytoin: increased meperidine metabolism and decreased effects
• Moderate to severe pain
• Preoperative sedation
• Analgesia during labor
• Moderate to severe pain
• Preoperative sedation
• Analgesia during labor
• Pethidine Injection 50mg / 1ml : 10 ampoules/box
• Pethidine Injection 100mg / 2ml : 10 ampoules/box
• Pethidine Injection 50mg / 1ml : 10 ampoules/box
• Pethidine Injection 100mg / 2ml : 10 ampoules/box
Route Onset Peak Duration
IM, SC 10–15 min 30–60 min 2–4 hr
IV Immediate 5–7 min 2–4 hr
Metabolism: Hepatic; T1/2: 3–8 hr
Distribution: Crosses placenta; enters breast milk
Excretion: Urine
Route Onset Peak Duration
IM, SC 10–15 min 30–60 min 2–4 hr
IV Immediate 5–7 min 2–4 hr
Metabolism: Hepatic; T1/2: 3–8 hr
Distribution: Crosses placenta; enters breast milk
Excretion: Urine
Analgesic, adjunct to anesthesia
[view] =>Analgesic, adjunct to anesthesia
) ) [field_precautions] => Array ( [0] => Array ( [value] => Use cautiously in: • head trauma; increased intracranial pressure (ICP); severe renal, hepatic, or pulmonary disease; hypothyroidism; adrenal insufficiency; extensive burns; alcoholism • undiagnosed abdominal pain or prostatic hyperplasia • elderly or debilitated patients • pregnant patients (not recommended before labor) • labor (drug may cause respiratory depression in neonate) • breastfeeding patients • children. [format] => 1 [safe] =>Use cautiously in:
• head trauma; increased intracranial pressure (ICP); severe renal, hepatic, or pulmonary disease; hypothyroidism; adrenal insufficiency; extensive burns; alcoholism
• undiagnosed abdominal pain or prostatic hyperplasia
• elderly or debilitated patients
• pregnant patients (not recommended before labor)
• labor (drug may cause respiratory depression in neonate)
• breastfeeding patients
• children.
Use cautiously in:
• head trauma; increased intracranial pressure (ICP); severe renal, hepatic, or pulmonary disease; hypothyroidism; adrenal insufficiency; extensive burns; alcoholism
• undiagnosed abdominal pain or prostatic hyperplasia
• elderly or debilitated patients
• pregnant patients (not recommended before labor)
• labor (drug may cause respiratory depression in neonate)
• breastfeeding patients
• children.
category B
[view] =>category B
) ) [field_references] => Array ( [0] => Array ( [value] => [format] => [safe] => [view] => ) ) [field_side_effects] => Array ( [0] => Array ( [value] => CNS: confusion, sedation, dysphoria, euphoria, floating feeling, hallucinations, headache, unusual dreams, seizures CV: hypotension, bradycardia, cardiac arrest, shock EENT: blurred vision, diplopia, miosis GI: nausea, vomiting, constipation, ileus, biliary tract spasms GU: urinary retention Respiratory: respiratory depression, respiratory arrest Skin: flushing, sweating, induration Other: pain at injection site, local irritation, physical or psychological drug dependence, drug tolerance [format] => 1 [safe] =>CNS: confusion, sedation, dysphoria, euphoria, floating feeling, hallucinations, headache, unusual dreams, seizures
CV: hypotension, bradycardia, cardiac arrest, shock
EENT: blurred vision, diplopia, miosis
GI: nausea, vomiting, constipation, ileus, biliary tract spasms
GU: urinary retention
Respiratory: respiratory depression, respiratory arrest
Skin: flushing, sweating, induration
Other: pain at injection site, local irritation, physical or psychological drug dependence, drug tolerance
CNS: confusion, sedation, dysphoria, euphoria, floating feeling, hallucinations, headache, unusual dreams, seizures
CV: hypotension, bradycardia, cardiac arrest, shock
EENT: blurred vision, diplopia, miosis
GI: nausea, vomiting, constipation, ileus, biliary tract spasms
GU: urinary retention
Respiratory: respiratory depression, respiratory arrest
Skin: flushing, sweating, induration
Other: pain at injection site, local irritation, physical or psychological drug dependence, drug tolerance
• Store below 30 C°
• Protect from light and freezing
• Store below 30 C°
• Protect from light and freezing
Analgesic
[view] =>Analgesic
) ) [field_related_products] => Array ( [0] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [view] => ) [1] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [view] => ) [2] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [view] => ) ) [taxonomy] => Array ( [2] => stdClass Object ( [tid] => 2 [vid] => 1 [name] => Anlagesics, Anti-inflammatory Drugs [description] => [weight] => 0 [language] => [trid] => 0 [v_weight_unused] => 0 ) ) [build_mode] => 0 [readmore] => [content] => Array ( [field_one_image] => Array ( [#type_name] => product [#context] => full [#field_name] => field_one_image [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => -3 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => image_plain [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_one_image [#weight] => 0 [#theme] => imagefield_formatter_image_plain [#item] => Array ( [fid] => 149 [uid] => 1 [filename] => pethidine_50_s.jpg [filepath] => sites/default/files/images/pethidine_50_s.jpg [filemime] => image/jpeg [filesize] => 78003 [status] => 1 [timestamp] => 1329481761 [list] => 1 [data] => Array ( [alt] => [title] => ) [i18nsync] => 1 [nid] => 214 [#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] => ) [#title] => [#description] => [#children] => [#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_one_image [#title] => Image [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] => [#printed] => 1 ) [#title] => [#description] => [#children] =>-
[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>-
) [#title] => [#description] => [#children] =>-
[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_brand_name [#title] => Brand Name [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>-
[#printed] => 1 ) [#title] => [#description] => [#children] =>-
Injection 100mg/2ml - Injection 50mg/1m
[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>Injection 100mg/2ml - Injection 50mg/1m
) [#title] => [#description] => [#children] =>Injection 100mg/2ml - Injection 50mg/1m
[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_dosage_form [#title] => Dosage Form [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>Injection 100mg/2ml - Injection 50mg/1m
[#printed] => 1 ) [#title] => [#description] => [#children] =>Injection 100mg/2ml - Injection 50mg/1m
Analgesic, adjunct to anesthesia
[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>Analgesic, adjunct to anesthesia
) [#title] => [#description] => [#children] =>Analgesic, adjunct to anesthesia
[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_pharmacological_category [#title] => Pharmacological Category [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>Analgesic, adjunct to anesthesia
[#printed] => 1 ) [#title] => [#description] => [#children] =>Analgesic, adjunct to anesthesia
Analgesic
[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>Analgesic
) [#title] => [#description] => [#children] =>Analgesic
[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_therapeutic_category [#title] => Therapeutic Category [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>Analgesic
[#printed] => 1 ) [#title] => [#description] => [#children] =>Analgesic
category B
[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>category B
) [#title] => [#description] => [#children] =>category B
[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_pregnancy_category [#title] => Pregnancy Category [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>category B
[#printed] => 1 ) [#title] => [#description] => [#children] =>category B
Binds to and depresses opiate receptors in spinal cord and CNS, altering perception of and response to pain
[#title] => [#description] => [#printed] => 1 ) [field_pharmacokinetics] => Array ( [#type_name] => product [#context] => full [#field_name] => field_pharmacokinetics [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => 4 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => default [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_pharmacokinetics [#weight] => 0 [#theme] => text_formatter_default [#item] => Array ( [value] => Route Onset Peak Duration IM, SC 10–15 min 30–60 min 2–4 hr IV Immediate 5–7 min 2–4 hr Metabolism: Hepatic; T1/2: 3–8 hr Distribution: Crosses placenta; enters breast milk Excretion: Urine [format] => 1 [safe] =>Route Onset Peak Duration
IM, SC 10–15 min 30–60 min 2–4 hr
IV Immediate 5–7 min 2–4 hr
Metabolism: Hepatic; T1/2: 3–8 hr
Distribution: Crosses placenta; enters breast milk
Excretion: Urine
Route Onset Peak Duration
IM, SC 10–15 min 30–60 min 2–4 hr
IV Immediate 5–7 min 2–4 hr
Metabolism: Hepatic; T1/2: 3–8 hr
Distribution: Crosses placenta; enters breast milk
Excretion: Urine
Route Onset Peak Duration
IM, SC 10–15 min 30–60 min 2–4 hr
IV Immediate 5–7 min 2–4 hr
Metabolism: Hepatic; T1/2: 3–8 hr
Distribution: Crosses placenta; enters breast milk
Excretion: Urine
Route Onset Peak Duration
IM, SC 10–15 min 30–60 min 2–4 hr
IV Immediate 5–7 min 2–4 hr
Metabolism: Hepatic; T1/2: 3–8 hr
Distribution: Crosses placenta; enters breast milk
Excretion: Urine
Route Onset Peak Duration
IM, SC 10–15 min 30–60 min 2–4 hr
IV Immediate 5–7 min 2–4 hr
Metabolism: Hepatic; T1/2: 3–8 hr
Distribution: Crosses placenta; enters breast milk
Excretion: Urine
• Moderate to severe pain
• Preoperative sedation
• Analgesia during labor
• Moderate to severe pain
• Preoperative sedation
• Analgesia during labor
• Moderate to severe pain
• Preoperative sedation
• Analgesia during labor
• Moderate to severe pain
• Preoperative sedation
• Analgesia during labor
• Moderate to severe pain
• Preoperative sedation
• Analgesia during labor
• Hypersensitivity to drug or bisulfites (with some injectable products)
• MAO inhibitor use within past 14 days
• Hypersensitivity to drug or bisulfites (with some injectable products)
• MAO inhibitor use within past 14 days
• Hypersensitivity to drug or bisulfites (with some injectable products)
• MAO inhibitor use within past 14 days
• Hypersensitivity to drug or bisulfites (with some injectable products)
• MAO inhibitor use within past 14 days
• Hypersensitivity to drug or bisulfites (with some injectable products)
• MAO inhibitor use within past 14 days
Use cautiously in:
• head trauma; increased intracranial pressure (ICP); severe renal, hepatic, or pulmonary disease; hypothyroidism; adrenal insufficiency; extensive burns; alcoholism
• undiagnosed abdominal pain or prostatic hyperplasia
• elderly or debilitated patients
• pregnant patients (not recommended before labor)
• labor (drug may cause respiratory depression in neonate)
• breastfeeding patients
• children.
Use cautiously in:
• head trauma; increased intracranial pressure (ICP); severe renal, hepatic, or pulmonary disease; hypothyroidism; adrenal insufficiency; extensive burns; alcoholism
• undiagnosed abdominal pain or prostatic hyperplasia
• elderly or debilitated patients
• pregnant patients (not recommended before labor)
• labor (drug may cause respiratory depression in neonate)
• breastfeeding patients
• children.
Use cautiously in:
• head trauma; increased intracranial pressure (ICP); severe renal, hepatic, or pulmonary disease; hypothyroidism; adrenal insufficiency; extensive burns; alcoholism
• undiagnosed abdominal pain or prostatic hyperplasia
• elderly or debilitated patients
• pregnant patients (not recommended before labor)
• labor (drug may cause respiratory depression in neonate)
• breastfeeding patients
• children.
Use cautiously in:
• head trauma; increased intracranial pressure (ICP); severe renal, hepatic, or pulmonary disease; hypothyroidism; adrenal insufficiency; extensive burns; alcoholism
• undiagnosed abdominal pain or prostatic hyperplasia
• elderly or debilitated patients
• pregnant patients (not recommended before labor)
• labor (drug may cause respiratory depression in neonate)
• breastfeeding patients
• children.
Use cautiously in:
• head trauma; increased intracranial pressure (ICP); severe renal, hepatic, or pulmonary disease; hypothyroidism; adrenal insufficiency; extensive burns; alcoholism
• undiagnosed abdominal pain or prostatic hyperplasia
• elderly or debilitated patients
• pregnant patients (not recommended before labor)
• labor (drug may cause respiratory depression in neonate)
• breastfeeding patients
• children.
Antihistamines, sedative-hypnotics: additive CNS depression
Barbiturates, cimetidine, protease inhibitor antiretrovirals: increased respiratory and CNS depression
Chlorpromazine, thioridazine: increased risk of pethedine toxicity
MAO inhibitors, procarbazine: potentially fatal reaction
Opioid agonist-antagonists: precipitation of opioid withdrawal in physically dependent patients
Phenytoin: increased meperidine metabolism and decreased effects
Antihistamines, sedative-hypnotics: additive CNS depression
Barbiturates, cimetidine, protease inhibitor antiretrovirals: increased respiratory and CNS depression
Chlorpromazine, thioridazine: increased risk of pethedine toxicity
MAO inhibitors, procarbazine: potentially fatal reaction
Opioid agonist-antagonists: precipitation of opioid withdrawal in physically dependent patients
Phenytoin: increased meperidine metabolism and decreased effects
Antihistamines, sedative-hypnotics: additive CNS depression
Barbiturates, cimetidine, protease inhibitor antiretrovirals: increased respiratory and CNS depression
Chlorpromazine, thioridazine: increased risk of pethedine toxicity
MAO inhibitors, procarbazine: potentially fatal reaction
Opioid agonist-antagonists: precipitation of opioid withdrawal in physically dependent patients
Phenytoin: increased meperidine metabolism and decreased effects
Antihistamines, sedative-hypnotics: additive CNS depression
Barbiturates, cimetidine, protease inhibitor antiretrovirals: increased respiratory and CNS depression
Chlorpromazine, thioridazine: increased risk of pethedine toxicity
MAO inhibitors, procarbazine: potentially fatal reaction
Opioid agonist-antagonists: precipitation of opioid withdrawal in physically dependent patients
Phenytoin: increased meperidine metabolism and decreased effects
Antihistamines, sedative-hypnotics: additive CNS depression
Barbiturates, cimetidine, protease inhibitor antiretrovirals: increased respiratory and CNS depression
Chlorpromazine, thioridazine: increased risk of pethedine toxicity
MAO inhibitors, procarbazine: potentially fatal reaction
Opioid agonist-antagonists: precipitation of opioid withdrawal in physically dependent patients
Phenytoin: increased meperidine metabolism and decreased effects
CNS: confusion, sedation, dysphoria, euphoria, floating feeling, hallucinations, headache, unusual dreams, seizures
CV: hypotension, bradycardia, cardiac arrest, shock
EENT: blurred vision, diplopia, miosis
GI: nausea, vomiting, constipation, ileus, biliary tract spasms
GU: urinary retention
Respiratory: respiratory depression, respiratory arrest
Skin: flushing, sweating, induration
Other: pain at injection site, local irritation, physical or psychological drug dependence, drug tolerance
CNS: confusion, sedation, dysphoria, euphoria, floating feeling, hallucinations, headache, unusual dreams, seizures
CV: hypotension, bradycardia, cardiac arrest, shock
EENT: blurred vision, diplopia, miosis
GI: nausea, vomiting, constipation, ileus, biliary tract spasms
GU: urinary retention
Respiratory: respiratory depression, respiratory arrest
Skin: flushing, sweating, induration
Other: pain at injection site, local irritation, physical or psychological drug dependence, drug tolerance
CNS: confusion, sedation, dysphoria, euphoria, floating feeling, hallucinations, headache, unusual dreams, seizures
CV: hypotension, bradycardia, cardiac arrest, shock
EENT: blurred vision, diplopia, miosis
GI: nausea, vomiting, constipation, ileus, biliary tract spasms
GU: urinary retention
Respiratory: respiratory depression, respiratory arrest
Skin: flushing, sweating, induration
Other: pain at injection site, local irritation, physical or psychological drug dependence, drug tolerance
CNS: confusion, sedation, dysphoria, euphoria, floating feeling, hallucinations, headache, unusual dreams, seizures
CV: hypotension, bradycardia, cardiac arrest, shock
EENT: blurred vision, diplopia, miosis
GI: nausea, vomiting, constipation, ileus, biliary tract spasms
GU: urinary retention
Respiratory: respiratory depression, respiratory arrest
Skin: flushing, sweating, induration
Other: pain at injection site, local irritation, physical or psychological drug dependence, drug tolerance
CNS: confusion, sedation, dysphoria, euphoria, floating feeling, hallucinations, headache, unusual dreams, seizures
CV: hypotension, bradycardia, cardiac arrest, shock
EENT: blurred vision, diplopia, miosis
GI: nausea, vomiting, constipation, ileus, biliary tract spasms
GU: urinary retention
Respiratory: respiratory depression, respiratory arrest
Skin: flushing, sweating, induration
Other: pain at injection site, local irritation, physical or psychological drug dependence, drug tolerance
• Store below 30 C°
• Protect from light and freezing
• Store below 30 C°
• Protect from light and freezing
• Store below 30 C°
• Protect from light and freezing
• Store below 30 C°
• Protect from light and freezing
• Store below 30 C°
• Protect from light and freezing
• Pethidine Injection 50mg / 1ml : 10 ampoules/box
• Pethidine Injection 100mg / 2ml : 10 ampoules/box
• Pethidine Injection 50mg / 1ml : 10 ampoules/box
• Pethidine Injection 100mg / 2ml : 10 ampoules/box
• Pethidine Injection 50mg / 1ml : 10 ampoules/box
• Pethidine Injection 100mg / 2ml : 10 ampoules/box
• Pethidine Injection 50mg / 1ml : 10 ampoules/box
• Pethidine Injection 100mg / 2ml : 10 ampoules/box
• Pethidine Injection 50mg / 1ml : 10 ampoules/box
• Pethidine Injection 100mg / 2ml : 10 ampoules/box
-
Injection 100mg/2ml - Injection 50mg/1m
Analgesic, adjunct to anesthesia
Analgesic
category B
Binds to and depresses opiate receptors in spinal cord and CNS, altering perception of and response to pain
Route Onset Peak Duration
IM, SC 10–15 min 30–60 min 2–4 hr
IV Immediate 5–7 min 2–4 hr
Metabolism: Hepatic; T1/2: 3–8 hr
Distribution: Crosses placenta; enters breast milk
Excretion: Urine
• Moderate to severe pain
• Preoperative sedation
• Analgesia during labor
• Hypersensitivity to drug or bisulfites (with some injectable products)
• MAO inhibitor use within past 14 days
Use cautiously in:
• head trauma; increased intracranial pressure (ICP); severe renal, hepatic, or pulmonary disease; hypothyroidism; adrenal insufficiency; extensive burns; alcoholism
• undiagnosed abdominal pain or prostatic hyperplasia
• elderly or debilitated patients
• pregnant patients (not recommended before labor)
• labor (drug may cause respiratory depression in neonate)
• breastfeeding patients
• children.
Antihistamines, sedative-hypnotics: additive CNS depression
Barbiturates, cimetidine, protease inhibitor antiretrovirals: increased respiratory and CNS depression
Chlorpromazine, thioridazine: increased risk of pethedine toxicity
MAO inhibitors, procarbazine: potentially fatal reaction
Opioid agonist-antagonists: precipitation of opioid withdrawal in physically dependent patients
Phenytoin: increased meperidine metabolism and decreased effects
CNS: confusion, sedation, dysphoria, euphoria, floating feeling, hallucinations, headache, unusual dreams, seizures
CV: hypotension, bradycardia, cardiac arrest, shock
EENT: blurred vision, diplopia, miosis
GI: nausea, vomiting, constipation, ileus, biliary tract spasms
GU: urinary retention
Respiratory: respiratory depression, respiratory arrest
Skin: flushing, sweating, induration
Other: pain at injection site, local irritation, physical or psychological drug dependence, drug tolerance
• Store below 30 C°
• Protect from light and freezing
• Pethidine Injection 50mg / 1ml : 10 ampoules/box
• Pethidine Injection 100mg / 2ml : 10 ampoules/box
(C) Copyright Caspian Tamin Pharmaceutical Co.
All Rights Reserved.